A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)-Reference-Cited by-同舟云学术

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

Published:2010-03-06 Issue:5 Volume:29 Page:1038-1044
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Viéitez José María,Valladares Manuel,Peláez Ignacio,de Sande González Luis,García-Foncillas Jesús,García-López José Luis,García-Girón Carlos,Reboredo Margarita,Bovio Humberto,Lacave Angel Jiménez

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-010-9400-z.pdf

Reference30 articles.

1. Cappuzzo F, Finocchiaro G, Rossi E et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717–723

2. Macarulla T, Ramos FJ, Capdevila J et al (2006) Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer 6:265–272

3. Mead GM (1996) Raltitrexed, a new drug for advanced colorectal cancer. Lancet 347:1568–1569

4. Zalcberg JR, Cunningham D, Van Cutsem E et al (1996) ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 14:716–721

5. Aparicio J, Vicent JM, Maestu I et al (2003) Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 14:1121–1125

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer;Current Treatment Options in Oncology;2021-06-07

2. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis;Cancer Research and Treatment;2017-07-15

3. Second-line systemic therapy for metastatic colorectal cancer;Cochrane Database of Systematic Reviews;2017-01-27

4. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials;Cancer Treatment Reviews;2014-06

5. Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells;Oncology Reports;2014-02-20